Enhanced Docetaxel Liposomal Composition for Targeted Tumor Delivery

The present invention relates to an improved docetaxel liposomal composition with enhanced stability, targeted tumor delivery, and increased anti-tumor activity. The inventive concept addresses the limitations of the original patent by incorporating a tumor-specific antibody, optimizing the pH, and combining with a second therapeutic agent.

The original patent disclosed a docetaxel liposomal composition with high drug loading, but it had limitations in terms of stability, residence time in blood, and tumor targeting. The present invention solves these problems by introducing a tumor-specific antibody conjugated to the liposome surface, optimizing the pH to less than 3.2, and combining the composition with a second therapeutic agent.

The inventive concept comprises a liposomal composition consisting of docetaxel, phospholipids, cholesterol, and a pH adjusting agent. The composition is prepared by mixing docetaxel with a combination of solvents, followed by lyophilization and reconstitution, resulting in a composition with more than 90% drug loading. The pH of the composition is optimized to less than 3.2, thereby improving the stability of the composition. Additionally, the composition is conjugated with a tumor-specific antibody, which increases the drug's residence time in blood and targets the tumor site. The composition can be administered intravenously and can be combined with a second therapeutic agent to increase the anti-tumor activity.

The novelty of the present invention lies in the combination of a tumor-specific antibody conjugated to the liposome surface, the optimized pH, and the combination with a second therapeutic agent. This inventive step provides a significant improvement over the original patent by enhancing the stability, targeted tumor delivery, and anti-tumor activity of the composition.

Alternative embodiments of the inventive concept include using different tumor-specific antibodies, varying the pH range, and combining with different therapeutic agents. Additionally, the composition can be administered through different routes, such as orally or topically, and can be used to treat different types of cancer.

The present invention has significant commercial potential in the pharmaceutical industry, particularly in the treatment of cancer. The targeted tumor delivery and increased anti-tumor activity of the composition make it an attractive option for cancer treatment. The market for cancer treatment is growing rapidly, and the present invention is well-positioned to capture a significant share of this market.